Drug Utilization Review (DUR) Meeting Minutes
March 7, 2011

Members Present: Norman Byers, Carrie Sorenson, Jeffrey Hostetter, John Savageau, David Clinkenbeard, Russ Sobotta, Cheryl Huber, Kim Krohn, Greg Pfister, Patricia Churchill, Steve Irsfeld
Members Absent: James Carlson, Leann Ness, Todd Twogood, Carlotta McCleary
Medicaid Pharmacy Department: Brendan Joyce, Gary Betting
HID Staff Present: Candace Rieth

Chair, G. Pfister called the meeting to order at 1:08 pm. Chair, G. Pfister asked for a motion to approve the minutes from the December meeting. J. Hostetter moved that the minutes be approved and C. Huber seconded the motion. Chair, G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update
B. Joyce informed the board members that there is no budget update at this time. The budget is currently going through the legislative process.

Statin Second Review
A motion and second were made at the December meeting to place any new statin products on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Gilenya Second Review
A motion and second were made at the December meeting to place Gilenya on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with one audible dissent.

Xyrem Second Review
A motion and second were made at the December meeting to place Xyrem on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Antihistamines, PPIs, COX-II/NSAIDs, Revatio, Actoplus Met, Azasite/Quixin, Carisoprodol, Blood factors, Relistor, Sancuso, Nuvigil and Nucynta forms and criteria were reviewed. No changes were made to the forms or criteria that were reviewed.

Nuedexta Review
B. Joyce reviewed Nuedexta information with the Board. There was no public comment. After discussion, D. Clinkenbeard made a motion to place Nuedexta on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

Nexiclon Review
B. Joyce reviewed Nexiclon information with the Board. There was no public comment. After discussion, P. Churchill made a motion to place Nexiclon on prior authorization. N. Byers seconded the motion. This topic will be brought up at the next meeting for finalization.

Topical Ketoconazole Products Review
B. Joyce reviewed topical ketoconazole product information with the Board. There was no public comment. After discussion, S. Irsfeld made a motion to place topical ketoconazole products on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Granisol Review
B. Joyce reviewed Granisol information with the Board. There was no public comment. After discussion, J. Hostetter made a motion to place Granisol on prior authorization and include it on the Sancuso form. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. S. Irsfeld moved to approve the new criteria and J. Savageau seconded the motion. Chair, G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held June 6, 2011. J. Hostetter made a motion to adjourn the meeting. C. Huber seconded. The motion passed with no audible dissent. Chair G. Pfister adjourned the meeting at 2:15 pm.